Portal hypotensive effects of combined terlipressin and DL-028, a synthetic α1 adrenoceptor antagonist administration on anesthetized portal hypertensive rats

Liver

Volumn 19, Issue 2, 1999, Pages 129-134

  Huang, Yi Tsau ^a   Lin, Li Chih ^a   Chern, Ji Wang ^b   Lin, Han Chieh ^a,c   Hong, Chuang Ye ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

1 adrenoceptor antagonist; Hemodynamics; Portal hypertension; Terlipressin

Indexed keywords

3 [[4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]METHYL] 2,3 DIHYDROIMIDAZO[1,2 C]QUINAZOLIN 5(6H) ONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; TERLIPRESSIN; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BILE DUCT LIGATION; MEAN ARTERIAL PRESSURE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; RAT; VEIN LIGATION;

ADRENERGIC ALPHA-ANTAGONISTS; ANESTHESIA; ANIMALS; ANTIHYPERTENSIVE AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HYPERTENSION, PORTAL; LYSINE VASOPRESSIN; MALE; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; VENOUS PRESSURE;

EID: 0033041077     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. GENECIN P, GROSZMANN R J. The biology of portal hypertension. In: ARIAS I M, BOYER J L, FAUSTO N, et al. ed. The liver: biology and pathobiology. 3rd Edn. New York: Raven Press, 1994: 1327-41.
2. D'AMICO G, PAGLIARO L, BOSCH J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332-54.
3. LEBREC D. Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding. Pharmacol Ther 1994; 61: 65-107.
4. WALKER S. Vasoconstrictor therapy in bleeding esophageal varices. Hepato-gastroenterology 1990; 37: 538-43.
5. GROSZMANN R J, KRAVETZ D, BOSCH J, et al. Nitroglycerin improves the hemodynamic responses to vasopressin in portal hypertension. Hepatology 1982; 2: 757-62.
6. TSAI Y-T, LAY C-S, LAI K-H, et al. Controlled trial of vasopressin plus nitroglycerin vs. vasopressin alone in the treatment of bleeding esophageal varices. Hepatology 1986; 6: 406-9.
7. GIMSON A E S, WESTABY D, HAYES P C, et al. A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology 1986; 6: 410-3.
8. IKEDA M. Effect of phenoxybenzamine (POB) on portal venous pressure in patients with portal hypertension. Am J Gastroenterol 1979; 71: 389-94.
9. MILLS P R, RAE A P, FARAH D A, et al. Comparison of three adrenoceptor blocking agents in patients with cirrhosis and portal hypertension. Am J Gastroenterol 1984; 25: 73-8.
10. CUMMINGS S A, KAUMANN A J, GROSZMANN R J. Comparison of the hemodynamic responses to ketanserin and prazosin in portal hypertensive rats. Hepatology 1988; 8: 1111-5.
11. 1 and β-adrenergic antagonists and 5-hydroxytryptamine receptor antagonist on portal-systemic collateral vascular resistance in conscious rats with portal hypertension. J Gastroenterol Hepatol 1992; 7: 449-54.
12. ALBILLOS A, LLEDO J L, BANARES R, et al. Hemodynamic effects of α-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. Hepatology 1994; 20: 611-7.
13. ALBILLOS A, LLEDO J L, ROSSI I, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995; 109: 1257-65.
14. 1-adrenoceptor antagonists and antihypertensive agents. J Med Chem 1993; 36: 2196-207.
15. HUANG Y-T, LIN L-C, CHERN J-W, LIN H-C, HONG C-Y. Portal hypotensive effects of DL-028 and prazosin on portal hypertensive rats. Pharmacology 1998; 57: 132-8.
16. BOSCH J, LEBREC D, JENKINS S A. Development of analogues: successes and failures. Scand J Gastroenterol 1998; 33 (Suppl 226): 3-13.
17. CHOJKIER M, GROSZMANN R J. Measurement of portal systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981; 240: G371-5.
18. HUANG Y-T, WANG, G-F, YANG M C M, et al. Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement. J Pharmacol Exp Ther 1996; 278: 535-41.
19. KOUNTOURAS J, BILLING B H, SCHEUER P J. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984; 65: 305-11.
20. COLOMBATO L A, ROBIN M, POMIER-LAYRARGUES G, HUET P-M. Animal models of portal hypertension. In: HOLSTEGE A, HAHN E G, SCHOLMERICH J eds. Portal hypertension. London: Kluwer Academic Publishers, 1995: 3-14.
21. JIMINEZ W, CLARIA J, ARROYO V. Experimental cirrhosis and pathogenesis of ascited formation in chronic liver disease. In: HOLSTEGE A, HAHN E G, SCHOLMERICH J eds. Portal Hypertension. London: Kluwer Academic Publishers, 1995: 15-32.
22. HUANG Y-T, TSAI J-F, LIN H-C, CHEN C-F, HONG C-Y. Hemodynamic effects of acute tetrandrine and terlipressin administration on portal hypertensive rats. Can J Physiol Pharmacol 1997; 75: 1220-5 (Erratum: 1998; 76: 467).
23. HUANG Y-T, WU H-L, CHERN J-W, LIN H-C, HONG C-Y. Hemodynamic effects of 8-day DL-028 and octreotide administration in rats with portal hypertension. Scand J Gastroenterol 1998, in press.
24. VACHIERY F, MOREAU R, GADANO A, et al. Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselective β-blocker. Dig Dis Sci 1996; 41: 1722-6.
25. LEE F-Y, TSAI Y-T, LIN H-C, et al. Hemodynamic effects of a combination of vasopressin and ketanserin in patients with hepatitis B-related cirrhosis. J Hepatol 1992; 15: 54-8.
26. HORI N, OKANOUE T, SAWA Y, et al. Hemodynamic effects of combined treatment with somatostatin analogue (SMS 201-995) and low-dose isosorbide dinitrate on portal hypertension in conscious cirrhotic rats. J Gastroenterol 1994; 29: 460-8.
27. KROEGER R J, GROSZMANN R J. The effect of the combination of nitroglycerin and propranolol on splanchnic and systemic hemodynamics in a portal hypertensive rat model. Hepatology 1985; 5: 425-30.
28. VAN DE CASTEELE M, ROEY G V, NEVENS F, FEVERY J. Effects of varying doses of spironolactone without and with nitrates on portal vein pressure and kidney function in partial portal vein ligated rats. Hepatology 1996; 24: 1492-6.
29. ROULOT D, GAUDIN C, BRAILLON A, et al. Hemodynamic effects of a combination of clonidine and propranolol in conscious cirrhotic rats. Can J Physiol Pharmacol 1989; 67: 1369-72.
30. HADENGUE A, MOREAU R, CERINI R, et al. Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: search for an additive effect. Hepatology 1989; 9: 83-7.
31. MOREAU R, CAILMAIL S, LEBREC D. Effects of vasopressin on haemodynamics in portal hypertensive rats receiving clonidine. Liver 1994; 14: 45-9.
32. SOGNI P, SOUPISON T, MOREAU R. et al. Hemodynamic effects of acute administration of furosemide in patients with cirrhosis receiving β-adrenergic antagonists. J Hepatol 1994; 20: 548-52.
33. OBERTI F, RIFFLET H, MAIGA M Y, et al. Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation. J Hepatol 1997; 26: 167-73.
34. LIN H-C, TSAI Y-T, LEE F-Y, et al. Systemic and portal haemodynamic changes following triglycyllysine vasopressin plus nitroglycerin administration in patients with hepatitis B-related cirrhosis. J Hepatol 1990; 10: 370-4.